Advertisement

International Journal of Hematology

, Volume 97, Issue 4, pp 540–543 | Cite as

Successful salvage therapy using lenalidomide in a patient with relapsed multiple myeloma after allogeneic hematopoietic stem cell transplantation

  • Tomotaka Suzuki
  • Shigeru KusumotoEmail author
  • Tatsuya Yoshida
  • Fumiko Mori
  • Asahi Ito
  • Masaki Ri
  • Takashi Ishida
  • Hirokazu Komatsu
  • Akio Niimi
  • Shinsuke Iida
Letter to the Editor
A 34-year-old Japanese man was diagnosed in 2008 as having stage III symptomatic multiple myeloma (IgD-lambda type) as defined by the Durie Salmon and International staging system. Chromosomal analysis revealed a normal karyotype, although overexpression of Cyclin D1 was detected by reverse-transcription/real-time polymerase chain reaction assay. After three cycles of induction chemotherapy with vincristine, doxorubicin, and dexamethasone, he received high-dose melphalan therapy with adjunct autologous peripheral blood stem cell transplantation (PBSCT). A very good partial response (VGPR) was achieved, although he relapsed at 11 months after PBSCT. Four cycles of bortezomib and dexamethasone therapy were subsequently given, resulting in a second VGPR. In March 2010, he underwent allogeneic bone marrow transplantation (BMT) from an HLA-matched unrelated donor. The conditioning regimen consisted of fludarabine (30 mg/m 2/day on days −8 to −3) and intravenous busulfan (3.2 mg/kg/day on...

Keywords

Multiple Myeloma Tacrolimus Bortezomib Lenalidomide Acute GVHD 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflict of interest

SI has received research funding from Celgene Corporation.

References

  1. 1.
    Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel J, Pérez-Simon JA, et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol. 2010;28:4521–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Galustian C, Dalgleish A. Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opin Pharmacother. 2009;10:125–33.PubMedCrossRefGoogle Scholar
  3. 3.
    Lioznov M, El-Cheikh J Jr, Hoffmann F, Hildebrandt Y, Ayuk F, Wolschke C, et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant. 2010;45:349–53.PubMedCrossRefGoogle Scholar
  4. 4.
    Coman T, Bachy E, Michallet M, Socie’ G, Uzunov M, Bourhis JH, et al. Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the SFGM-TC. Haematologica. 2012 Nov 9 [Epub ahead of print].Google Scholar
  5. 5.
    Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G, et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood. 2011;118:2413–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Kröger N, Zabelina T, Klyuchnikov E, Kropff M, Pflüger KH, Burchert A, et al. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. Bone Marrow Transplant. 2012 Aug 6 [Epub ahead of print].Google Scholar

Copyright information

© The Japanese Society of Hematology 2013

Authors and Affiliations

  • Tomotaka Suzuki
    • 1
  • Shigeru Kusumoto
    • 1
    Email author
  • Tatsuya Yoshida
    • 1
  • Fumiko Mori
    • 1
  • Asahi Ito
    • 1
  • Masaki Ri
    • 1
  • Takashi Ishida
    • 1
  • Hirokazu Komatsu
    • 1
  • Akio Niimi
    • 1
  • Shinsuke Iida
    • 1
  1. 1.Department of Medical Oncology and ImmunologyNagoya City University Graduate School of Medical SciencesNagoyaJapan

Personalised recommendations